BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 19962780)

  • 1. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
    Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Chiu YF; Kuo YH; Tsai MS; Lin YW
    Lung Cancer; 2010 Aug; 69(2):155-64. PubMed ID: 19962780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Rad51 down-regulation and extracellular signal-regulated kinases 1 and 2 inactivation in emodin and mitomycin C-induced synergistic cytotoxicity in human non-small-cell lung cancer cells.
    Su YJ; Tsai MS; Kuo YH; Chiu YF; Cheng CM; Lin ST; Lin YW
    Mol Pharmacol; 2010 Apr; 77(4):633-43. PubMed ID: 20042515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.
    Ko JC; Tsai MS; Kuo YH; Chiu YF; Weng SH; Su YC; Lin YW
    Biochem Pharmacol; 2011 Mar; 81(5):680-90. PubMed ID: 21168393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells.
    Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Lin YW
    Biochem Pharmacol; 2010 Feb; 79(4):655-64. PubMed ID: 19799875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation.
    Chen RS; Jhan JY; Su YJ; Lee WT; Cheng CM; Ciou SC; Lin ST; Chuang SM; Ko JC; Lin YW
    Exp Cell Res; 2009 Sep; 315(15):2658-72. PubMed ID: 19505457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).
    Tsai MS; Weng SH; Kuo YH; Chiu YF; Lin YW
    Mol Pharmacol; 2011 Jul; 80(1):136-46. PubMed ID: 21493726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells.
    Ko JC; Tsai MS; Chiu YF; Weng SH; Kuo YH; Lin YW
    J Pharmacol Exp Ther; 2011 Jul; 338(1):184-94. PubMed ID: 21444628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells.
    Ko JC; Tsai MS; Weng SH; Kuo YH; Chiu YF; Lin YW
    Toxicol Appl Pharmacol; 2011 Sep; 255(3):327-38. PubMed ID: 21810436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
    Ko JC; Ciou SC; Cheng CM; Wang LH; Hong JH; Jheng MY; Ling ST; Lin YW
    Carcinogenesis; 2008 Jul; 29(7):1448-58. PubMed ID: 18544565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA; Mountzios G; Soria JC
    Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
    Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
    Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.
    Ko JC; Ciou SC; Jhan JY; Cheng CM; Su YJ; Chuang SM; Lin ST; Chang CC; Lin YW
    Mol Cancer Res; 2009 Aug; 7(8):1378-89. PubMed ID: 19671683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
    Felip E; Rosell R
    Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.
    Cai Y; Yan X; Zhang G; Zhao W; Jiao S
    Oncotarget; 2015 Aug; 6(22):18997-9005. PubMed ID: 25944617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
    Weng SH; Tseng SC; Huang YC; Chen HJ; Lin YW
    Biochem Pharmacol; 2012 Jul; 84(1):126-36. PubMed ID: 22480737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
    Jiao JW; Wen F
    Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.